{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T06:49:56Z","timestamp":1778050196414,"version":"3.51.4"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>ACC patients\u2019 quality of life may be impacted by symptoms related to cancer or treatments, as well as emotional, spiritual, existential, social, economic, and sexual aspects. The aim was the development and psychometric validation of a new instrument (QoLACC) for measuring Patient-Reported Outcome in patients with ACC. The study was conducted from October 2024 to January 2025 at the Oncology Unit of Brescia's ASST. Fifteen patients and 15 physicians graded the comprehensibility\/difficulty and relevance of the items of QoLACC whereas 37 consecutive patients assessed psychometric validity. Comprehensibility, difficulty and clinical relevance of the items to include in the QoLACC questionnaire were assessed by selected ACC patients and clinicians. Validated scales were co-administered to the developed QoLACC questionnaire to assess physical and psychological symptoms, and the test-retest reliability and construct validity psychometric validation were performed. The QoLACC items showed excellent content validity [0.93-1.00] and acceptable to excellent comprehensibility [0.80-1.00] and difficulty [0.80-1.00], with minor exceptions. Item analysis showed good discriminant capability and response variability. The total questionnaire has good reliability (the intraclass correlation coefficient (ICC) was 0.870 [95% CI: 0.734-0.937]) and construct validity proved by the moderate to strong correlations [0.39-0.62] between the QoLACC and the EORTC item 29 and item 30, the QoLACC financial section and the COST (0.47), and the QoLACC spiritual section and the JSWBS (0.60). We defined and validated the Italian questionnaire aiming to explore ACC patients\u2019 quality of life, to help the Health Care Professionals to manage and support these patients.<\/jats:p>","DOI":"10.1093\/ejendo\/lvag052","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:47:35Z","timestamp":1773924455000},"page":"431-439","source":"Crossref","is-referenced-by-count":1,"title":["Quality of life questionnaire development and validation for adrenocortical carcinoma patients"],"prefix":"10.1093","volume":"194","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8457-122X","authenticated-orcid":false,"given":"Marta","family":"Lagan\u00e0","sequence":"first","affiliation":[{"name":"Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology Unit, University of Brescia at ASST Spedali Civili , Piazzale Spedali Civili 1, Brescia 25123 ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Cosentini","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology Unit, University of Brescia at ASST Spedali Civili , Piazzale Spedali Civili 1, Brescia 25123 ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nichole","family":"Farina","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology Unit, University of Brescia at ASST Spedali Civili , Piazzale Spedali Civili 1, Brescia 25123 ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Consoli","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology Unit, University of Brescia at ASST Spedali Civili , Piazzale Spedali Civili 1, Brescia 25123 ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlotta","family":"Tagliaferro","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Psychology, Drug, and Child's Health (NEUROFARBA), Section of Psychology, University of Florence , Florence 50100 ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Chiesi","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Psychology, Drug, and Child's Health (NEUROFARBA), Section of Psychology, University of Florence , Florence 50100 ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedetta","family":"Trevisan","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology Unit, University of Brescia at ASST Spedali Civili , Piazzale Spedali Civili 1, Brescia 25123 ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Cremaschi","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology Unit, University of Brescia at ASST Spedali Civili , Piazzale Spedali Civili 1, Brescia 25123 ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide Lorenzo","family":"Bettini","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology Unit, University of Brescia at ASST Spedali Civili , Piazzale Spedali Civili 1, Brescia 25123 ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"Berruti","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology Unit, University of Brescia at ASST Spedali Civili , Piazzale Spedali Civili 1, Brescia 25123 ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla Ida","family":"Ripamonti","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology Unit, University of Brescia at ASST Spedali Civili , Piazzale Spedali Civili 1, Brescia 25123 ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"issue":"4","key":"2026033103121304400_lvag052-B1","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-18-0608","article-title":"European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors","volume":"179","author":"Fassnacht","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"2026033103121304400_lvag052-B2","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/S2213-8587(23)00193-6","article-title":"Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study","volume":"11","author":"Terzolo","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026033103121304400_lvag052-B3","doi-asserted-by":"publisher","first-page":"vii131","DOI":"10.1093\/annonc\/mds231","article-title":"Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"23","author":"Berruti","year":"2012","journal-title":"Ann Oncol"},{"issue":"6","key":"2026033103121304400_lvag052-B4","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1530\/EJE-19-0570","article-title":"Activity and safety of temozolomide in advanced adrenocortical carcinoma patients","volume":"181","author":"Cosentini","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"2026033103121304400_lvag052-B5","doi-asserted-by":"publisher","first-page":"624102","DOI":"10.3389\/fendo.2021.624102","article-title":"Clinical prognostic factors in patients with metastatic adrenocortical carcinoma treated with second line gemcitabine plus capecitabine chemotherapy","volume":"12","author":"Grisanti","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"2026033103121304400_lvag052-B6","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1007\/s12020-022-03075-y","article-title":"Supportive therapies in patients with advanced adrenocortical carcinoma submitted to standard EDP-M regimen","volume":"77","author":"Turla","year":"2022","journal-title":"Endocrine"},{"issue":"7","key":"2026033103121304400_lvag052-B7","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1111\/bcp.14721","article-title":"Pharmacological profile and effects of mitotane in adrenocortical carcinoma","volume":"87","author":"Corso","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"2026033103121304400_lvag052-B8","doi-asserted-by":"publisher","first-page":"681","DOI":"10.3390\/biomedicines9060681","article-title":"Estrogen-like effect of mitotane explained by its agonist activity on estrogen receptor-\u03b1","volume":"9","author":"Rossini","year":"2021","journal-title":"Biomedicines"},{"issue":"1","key":"2026033103121304400_lvag052-B9","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s40425-019-0722-x","article-title":"Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma","volume":"7","author":"Habra","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"4","key":"2026033103121304400_lvag052-B10","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1097\/PPO.0b013e31829e3221","article-title":"Role of radiotherapy in adrenocortical carcinoma","volume":"19","author":"Ho","year":"2013","journal-title":"Cancer J"},{"issue":"5","key":"2026033103121304400_lvag052-B11","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.jamcollsurg.2008.01.018","article-title":"Open and laparoscopic adrenalectomy: analysis of the national surgical quality improvement program","volume":"206","author":"Lee","year":"2008","journal-title":"J Am Coll Surg"},{"issue":"13","key":"2026033103121304400_lvag052-B12","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1002\/cncr.24331","article-title":"Radiotherapy in adrenocortical carcinoma","volume":"115","author":"Polat","year":"2009","journal-title":"Cancer"},{"issue":"1","key":"2026033103121304400_lvag052-B13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40425-018-0487-7","article-title":"Correction to: serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients","volume":"7","author":"Zhao","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"5","key":"2026033103121304400_lvag052-B14","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S1470-2045(24)00095-0","article-title":"Cabozantinib monotherapy for advanced adrenocortical carcinoma: a single-arm, phase 2 trial","volume":"25","author":"Campbell","year":"2024","journal-title":"Lancet Oncol"},{"issue":"10","key":"2026033103121304400_lvag052-B15","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.3390\/cancers11101500","article-title":"Health-related quality of life in adrenocortical carcinoma","volume":"11","author":"Steenaard","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"34_suppl","key":"2026033103121304400_lvag052-B16","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1200\/JCO.2018.36.34_suppl.156","article-title":"Social isolation: impact on treatment and survival in patients with advanced cancer","volume":"36","author":"Moore","year":"2018","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026033103121304400_lvag052-B17","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s10865-017-9892-5","article-title":"Cancer-related loneliness mediates the relationships between social constraints and symptoms among cancer patients","volume":"41","author":"Adams","year":"2018","journal-title":"J Behav Med"},{"issue":"5","key":"2026033103121304400_lvag052-B18","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.ejon.2008.11.003","article-title":"The loneliness of cancer","volume":"12","author":"Wells","year":"2008","journal-title":"Eur J Oncol Nurs"},{"issue":"5","key":"2026033103121304400_lvag052-B19","doi-asserted-by":"publisher","first-page":"102992","DOI":"10.1016\/j.esmoop.2024.102992","article-title":"ESMO expert consensus statements on the screening and management of financial toxicity in patients with cancer","volume":"9","author":"Carrera","year":"2024","journal-title":"ESMO Open"},{"issue":"12","key":"2026033103121304400_lvag052-B20","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1093\/annonc\/mdw433","article-title":"The association of financial difficulties with clinical outcomes in cancer patients: secondary analysis of 16 academic prospective clinical trials conducted in Italy","volume":"27","author":"Perrone","year":"2016","journal-title":"Ann Oncol"},{"issue":"12","key":"2026033103121304400_lvag052-B21","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1200\/OP.24.00025","article-title":"Exploring the relationship among financial hardship, anxiety, and depression in patients with cancer: a longitudinal study","volume":"20","author":"Yanez","year":"2024","journal-title":"JCO Oncol Pract"},{"issue":"1","key":"2026033103121304400_lvag052-B22","doi-asserted-by":"publisher","first-page":"e000465","DOI":"10.1136\/esmoopen-2018-000465","article-title":"Interprofessional spiritual care in oncology: a literature review","volume":"4","author":"Puchalski","year":"2019","journal-title":"ESMO Open"},{"issue":"2","key":"2026033103121304400_lvag052-B23","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1001\/jama.2022.11086","article-title":"Spirituality in serious illness and health","volume":"328","author":"Balboni","year":"2022","journal-title":"JAMA"},{"issue":"10","key":"2026033103121304400_lvag052-B24","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1007\/s00520-024-08922-4","article-title":"Hope and spiritual well-being: two sides of the same coin?","volume":"32","author":"Ripamonti","year":"2024","journal-title":"Support Care Cancer"},{"issue":"5","key":"2026033103121304400_lvag052-B25","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s11017-024-09679-x","article-title":"Flourishing at the end of life","volume":"45","author":"Symons","year":"2024","journal-title":"Theor Med Bioeth"},{"issue":"6","key":"2026033103121304400_lvag052-B26","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1377\/hlthaff.2023.01643","article-title":"Spirituality as a determinant of health: emerging policies, practices, and systems: article examines spirituality as a social determinant of health","volume":"43","author":"Long","year":"2024","journal-title":"Health Aff (Millwood)"},{"issue":"1","key":"2026033103121304400_lvag052-B27","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1177\/02692163241287650","article-title":"Efficacy of spiritual interventions in palliative care: an umbrella review of systematic reviews","volume":"39","author":"Austin","year":"2025","journal-title":"Palliat Med"},{"issue":"5","key":"2026033103121304400_lvag052-B28","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"2026033103121304400_lvag052-B29","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1210\/jc.2011-1901","article-title":"Quality of life in European patients with Addison's disease: validity of the disease-specific questionnaire AddiQoL","volume":"97","author":"\u00d8ksnes","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026033103121304400_lvag052-B30","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1023\/A:1008264412398","article-title":"Evaluation of the EORTC QLQ-C30 questionnaire: a comparison with SF-36 Health Survey in a cohort of Italian long-survival cancer patients","volume":"9","author":"Apolone","year":"1998","journal-title":"Ann Oncol"},{"issue":"6","key":"2026033103121304400_lvag052-B31","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.3390\/cancers14061366","article-title":"Health-related quality of life in adrenocortical carcinoma: development of the disease-specific questionnaire ACC-QOL and results from the PROFILES registry","volume":"14","author":"Steenaard","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"20","key":"2026033103121304400_lvag052-B32","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.1002\/cncr.28814","article-title":"The development of a financial toxicity patient-reported outcome in cancer: the COST measure","volume":"120","author":"De Souza","year":"2014","journal-title":"Cancer"},{"issue":"3","key":"2026033103121304400_lvag052-B33","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/cncr.30369","article-title":"Measuring financial toxicity as a clinically relevant patient-reported outcome: the validation of the COmprehensive Score for financial Toxicity (COST)","volume":"123","author":"De Souza","year":"2017","journal-title":"Cancer"},{"issue":"9","key":"2026033103121304400_lvag052-B34","doi-asserted-by":"publisher","first-page":"4477","DOI":"10.1007\/s00520-019-05286-y","article-title":"The validation of the Italian version of the COmprehensive Score for financial Toxicity (COST)","volume":"28","author":"Ripamonti","year":"2020","journal-title":"Support Care Cancer"},{"issue":"6","key":"2026033103121304400_lvag052-B35","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1177\/0164027504268574","article-title":"A short scale for measuring loneliness in large surveys: results from two population-based studies","volume":"26","author":"Hughes","year":"2004","journal-title":"Res Aging"},{"issue":"6","key":"2026033103121304400_lvag052-B36","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/S0197-4572(96)80238-2","article-title":"Focus on spiritual well-being: harmonious interconnectedness of mind-body-spirit\u2014use of the JAREL spiritual well-being scale","volume":"17","author":"Hungelmann","year":"1996","journal-title":"Geriatr Nur (Lond)"},{"issue":"6","key":"2026033103121304400_lvag052-B37","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1080\/13674676.2019.1594740","article-title":"Italian validation of the jarel spiritual well-being scale","volume":"22","author":"Magnano","year":"2019","journal-title":"Ment Health Relig Cult"},{"issue":"1","key":"2026033103121304400_lvag052-B38","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1207\/s15327752jpa6601_2","article-title":"UCLA loneliness scale (version 3): reliability, validity, and factor structure","volume":"66","author":"Russell","year":"1996","journal-title":"J Pers Assess"},{"issue":"2","key":"2026033103121304400_lvag052-B39","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1177\/030089160208800206","article-title":"Quality of life in breast and colon cancer long-term survivors: an assessment with the Eortc Qlq-c30 and Sf-36 questionnaires","volume":"88","author":"Mosconi","year":"2002","journal-title":"Tumori J"},{"issue":"2","key":"2026033103121304400_lvag052-B40","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jcm.2016.02.012","article-title":"A guideline of selecting and reporting intraclass correlation coefficients for reliability research","volume":"15","author":"Koo","year":"2016","journal-title":"J Chiropr Med"},{"issue":"23","key":"2026033103121304400_lvag052-B41","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","article-title":"Combination chemotherapy in advanced adrenocortical carcinoma","volume":"366","author":"Fassnacht","year":"2012","journal-title":"N Engl J Med"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/advance-article-pdf\/doi\/10.1093\/ejendo\/lvag052\/67502064\/lvag052.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/194\/3\/431\/67502064\/lvag052.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/194\/3\/431\/67502064\/lvag052.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T07:12:17Z","timestamp":1774941137000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/194\/3\/431\/8539909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvag052","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,3]]}}}